MRI-Guided Breast Biopsies: Are Second-Look Ultrasounds Really Necessary?
"New research clarifies the role of second-look ultrasounds in breast cancer detection, helping to streamline the diagnostic process."
Breast Magnetic Resonance Imaging (MRI) is a powerful tool for detecting suspicious lesions, particularly those that are not apparent through traditional mammography or clinical examination. When these lesions are found, a biopsy is often necessary to determine whether they are cancerous. MRI-guided biopsies have become increasingly common, offering a precise way to sample these potentially problematic areas.
However, before resorting to an MRI-guided biopsy, doctors often use a targeted second-look ultrasound (SLUS) to see if the lesion can be visualized and biopsied using ultrasound guidance, a less expensive and more accessible technique. The question then becomes: what happens when the SLUS comes back negative – meaning the lesion isn't visible on ultrasound? Does this negative result influence the outcome of the subsequent MRI-guided biopsy?
A new study, published in the Canadian Association of Radiologists Journal, sheds light on this issue. Researchers investigated the outcomes of MRI-guided breast biopsies in women who had previously undergone a negative targeted SLUS. Their findings could help refine clinical practice, potentially reducing unnecessary procedures and improving the efficiency of breast cancer diagnosis.
MRI-Guided Biopsy: Uses and Challenges
Breast MRI is used to screen high-risk patients, stage breast cancer locally before surgery, and monitor neoadjuvant chemotherapy. It can help resolve indeterminate lesions when imaging results conflict with clinical assessment or core biopsy. MRI-guided breast biopsy is an essential tool, but the 2016 review describes the technique as challenging and imperfect, citing difficulties with adequate lesion sampling and confirming the biopsy result. The 2025 handout explains that tumor-associated blood vessels can cause rapid gadolinium uptake and washout within the first 1–2 minutes after administration.
How Breast Imaging Evolved
A historical review traces breast imaging technologies used for diagnosis and staging, including mammography, ultrasonography, MRI, computed tomography, and positron imaging. A 2013 review describes MRI as the most sensitive method for detecting invasive carcinoma and comparable to mammography for detecting ductal carcinoma in situ (DCIS). It also reports that MRI's specificity, false-positive, and biopsy rates were less favorable than those of screening mammography, limiting its use for general-population screening. Siemens Healthineers presents breast biopsy history as a progression from early pioneers to more recent developments.
Does a Negative Ultrasound Impact MRI Biopsy Results?
Researchers at the McGill University Health Centre and other institutions conducted a retrospective study involving 158 women with breast lesions detected by MRI. All patients were scheduled for an MRI-guided biopsy. The study looked at several factors, including whether patients had undergone a targeted SLUS prior to the MRI-guided biopsy, the characteristics of the lesions seen on MRI, and the final pathology results.
- Study Population: 158 women with MRI-detected breast lesions.
- SLUS Prior to MRI: 63% of the women (98 out of 155 lesions biopsied) had a targeted SLUS before the MRI-guided biopsy.
- Malignancy Rate: 15% of the biopsied lesions were found to be malignant.
- Benign vs. High-Risk: 68% of lesions were benign, and 17% were classified as high-risk.
- Key Finding: A negative SLUS did not influence the pathology outcome of lesions biopsied under MRI guidance.
Recent Reviews on Breast Cancer Detection
A 2025 review in Frontiers in Oncology surveys imaging, sensors, and molecular biotechnology as approaches developed to support early breast cancer detection. It notes that delayed detection is a major concern and that early diagnosis can improve prognosis and long-term survival. A 2024 article in the Journal of Breast Imaging highlights breast MRI as a recent advance alongside established methods such as mammography, with potential to improve cancer detection and patient outcomes. A May 2026 Diagnostic Imaging roundup covers April 2026 findings involving AI, digital breast tomosynthesis, breast MRI studies, and screening guidelines from the National Comprehensive Cancer Network and the American College of Physicians.
Comparisons Across Breast Imaging Methods
One study of palpable breast masses reported that ultrasound mammography was significantly more sensitive than X-ray mammography for diagnosing malignant masses: 98.7% versus 86.8% (p < 0.025). A separate comparison concluded that screen-film mammography and xeromammography were comparable for cancer detection when technique was optimal and personnel were experienced. Another study examined interpretation disagreements between full-field digital and film-screen mammography; its results covered six radiologists reviewing images from 1,147 breasts in 692 patients. The provided summary does not state the disagreement rate or its causes.
What This Means for Breast Cancer Detection
This research provides valuable insights for radiologists and other healthcare professionals involved in breast cancer diagnosis. The key takeaway is that a negative second-look ultrasound should not deter or undermine the importance of proceeding with an MRI-guided biopsy when a suspicious lesion is identified on MRI.
Emerging Directions in Breast Radiology
A 2023 review discusses established and novel breast MRI exams proposed for cancer detection and considerations for performing MRI in clinical practice; its summary says MRI is superior at identifying lesions in women with a very high risk. A review of the future of breast radiology describes imaging-guided therapies and theranostics as approaches that promise targeted precision treatment. It places these prospects in a field that has progressed since mammography began being used for screening in the early 1960s. An American Hospital Management article describes further anticipated developments in breast biopsy, including AI-driven diagnostics, minimally invasive techniques, and personalized medicine.
MRI’s Role in Breast Cancer Care
A review of MRI in breast cancer and breast conservation therapy reports that MRI's incremental cancer detection rate is high irrespective of breast density and menopausal status. It also says that, although MRI has a lower perceived positive predictive value, more recent published studies find its positive predictive value similar to mammography. A 2024 article describes contrast-enhanced breast MRI as having an established role in detecting, evaluating, and managing breast cancer, and discusses its evaluation for breast radiotherapy treatment planning. UpToDate’s 2025 overview covers MRI technique, interpretation, and indications alongside emerging detection tools and the roles of mammography and ultrasound in suspected disease.
These finding helps to reduce unnecessary procedures. By clarifying the role of SLUS in the diagnostic pathway, this study can contribute to more efficient and cost-effective breast cancer detection strategies.
While this study offers important clarity, further research could explore factors influencing the detection rate of SLUS and refine the selection criteria for MRI-guided biopsies to optimize diagnostic accuracy and patient outcomes.